Autopsy report · NCT04995094

Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma

“Enrollment challenges, study not feasible”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

HiberCell, Inc.

Sponsor type

Industry

Conditions

Pathologic Stage III Cutaneous Melanoma AJCC v8

Interventions

Imprime PGG; Pembrolizumab

Participants

0

Sites

4

Countries

United States

Trials that died the same way

• Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness
  “Enrollment challenges” (85% match in meaning)
• Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)
  “Difficult enrollment” (82% match in meaning)
• The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD
  “Study subject enrollment difficulties” (80% match in meaning)
• Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography
  “Poor enrollment due to insufficient study support.” (80% match in meaning)
• Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts
  “Difficulties of enrollment” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.